logo
logo

Synklino Completes Series A Raise Of Eur 29.8 Million To Advance Clinical Trials Of Its Drug Candidate For The Treatment Of Cytomegalovirus (Cmv)

Jun 08, 2022•about 3 years ago

Round Type

series a

Copenhagen

Description

Synklino, an emerging biotech company developing breakthrough drugs for the treatment of chronic viral infections, has completed a Series A fundraise of EUR 29.8 million (DKK 222 million / USD 31.9 million) accelerating its development plans towards significant clinical milestones.

Company Information

Company

Synklino

Location

Copenhagen, Capital Region Of Denmark, Denmark

About

Synklino is a Danish biotech company developing groundbreaking therapies against chronic viral infections. The company is owned by renowned Nordic funds and institutional investors Eir Ventures, The Danish Growth Fund and PKA as well as approximately 70 private shareholders. Synklino's first-in-class drug candidate SYN002 specifically targets cytomegalovirus infection in transplantation patients and aims to change the current antiviral treatment paradigm by providing radically different therapeutic opportunities and a path for transplant recipients to live a full life again. Synklino is a spinout from the University of Copenhagen and the Technical University of Denmark established to develop groundbreaking therapies against devastating viral infections. Synklino is incubated at the BioInnovation Institute in its prestigious Creation House program. Read more at synklino.com